RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide human immunology registry for infectious disease research. The new registry was developed to help clinicians and researchers better understand the human immune response to emerging and re-emerging infectious diseases.
Details about the registry:
http://www.remedymd.com/cer100/human_immunology.html
Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s human immunology registry will help researchers develop new vaccines to protect against infectious diseases such as:
and help researchers understand how the immune system develops its own protections and how harmless microorganisms in the lungs, intestines and other mucosal surfaces protect against harmful microbes that enter the body through these sites.
The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.
“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.